Email this article 
PECULIARITIES OF PLATELET ACTIVATION CHANGES IN PATIENTS WITH CHRONIC SCHIZOPHRENIA, DEPENDING ON THE SEVERITY OF POSITIVE AND NEGATIVE SYMPTOMS DURING THE REMISSION FORMATION
- Authors: Brusov O.S.1, Zlobina G.P.1
-
Affiliations:
- Mental Health Research Centre, Moscow, Russian Federation
- Issue: Vol 70, No 3 (2015)
- Pages: 355-359
- Section: SHORT MESSAGES
- URL: https://vestnikramn.spr-journal.ru/jour/article/view/42
- DOI: https://doi.org/10.15690/vramn.v70i3.1333
- ID: 42
Cite item
Full Text
Abstract
Objective: The aim of our study was to compare the changes in the severity of positive, negative and psychopathological PANSS symptoms which occur as an outcome of an attack in schizophrenic patients along with remission formation and the degree of platelet activation in these patients. Methods: Psychometric scale of the Positive and Negative Syndrome Scale (PANSS) and the method of estimation of platelet activation based on the calculation of cells number after elution from the column with sepharose CL-2B were used. Results: The changes in the severity of the disease were estimated using the PANSS scale of chronic schizophrenic patients in remission formation. An increase in platelet activation was determined on the basis of the above described quantitative parameter. Comparison of changes in platelet activation parameter with changes in the disease severity rating detected similar statistically indistinguishable (p >0.05) changes in the severity of positive symptoms and quantitative variable of platelet activation between the 1st and the 3rd visits in the period of remission formation. Platelet number after elution from the column during the 3rd visit was approximately two times less than during the 1st visit (p =0.002). PANSS positive subscale shows a decrease of the severity of the syndrome by 1.6 times (p <0.0002). In addition the difference between the platelet activation parameter and severity of the negative syndrome was fixed during the 3rd visit (p <0.034). Conclusion: Similar changes in the severity of positive syndrome and platelet activation parameter were presented from 1st to 3rd visit in the remission formation. A distinction was also made between the platelet activation parameter and severity of the negative syndrome was fixed during the 3rd visit.
Keywords
About the authors
O. S. Brusov
Mental Health Research Centre, Moscow, Russian Federation
Author for correspondence.
Email: oleg_brusov@mail.ru
кандидат биологических наук, заведующий лабораторией биохимии НЦ психического
здоровья
Адрес: 117152, Москва, Загородное ш., д. 2, корп. 3, стр. 16, тел.: +7 (495) 952-91-41
G. P. Zlobina
Mental Health Research Centre, Moscow, Russian Federation
Email: zlobina2000@mail.ru
кандидат биологических наук, старший научный сотрудник лаборатории биохимии НЦ
психического здоровья
Адрес: 117152, Москва, Загородное ш., д. 2, корп. 3, стр. 16, тел.: +7 (495) 952-91-41
References
- Davidson L., Schmutte T., Dinzeo T., Andres-Hyman R. Schizophr .Bull. 2008; 34 (1): 5–8.
- Harvey C.A., Jeffreys S.E., McNaught A.S., Bizard R.A., King M.B. Int. J. Soc. Psychiatry. 2007; 53 (4): 340–356.
- Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Weinberger D.R. Am. J. Psychiatry. 2005; 162 (3): 441–449.
- Emsley R., Chiliza B., Asmal L., Lehloenya K. Curr. Opin. Psychiatry. 2011; 24 (2): 114–121.
- Mortimer A.M. Brit. J. Psychiatry. 2007; 191 (50): 7–14.
- Kay S.R., Fiszbein A., Lindenmayer J.P., Opler L.A Acta Psychiatr. Scand. 1986; 74 (5): 507–518.
- Habets K.L., Huizinga T.W., Toes R.E. Eur. J. Clin. Invest. 2013; 43 (7): 746–757.
- Klinger M.H., Jelkmann W.J. Interferon. Cytokine Res. 2002; 22 (9): 913–922.
- Shcherbakova I.V., Kaleda V.G., Barkhatova A.N., Klyushnik T.P. Zhurnal nevrologii i psikhiatrii = Journal of neurology and psychiatry. 2005;105(3):43–46.
- Bonartsev P.D., Rakhmanova V.I., Bezrukov M.V., Faktor M.I., Brusov O.S., Uranova N.A. Zhurnal nevrologii i psikhiatrii = Journal of neurology and psychiatry. 2014;114(2):42–46.
- Brusov O.S., Zlobina G.P. Vestnik RAMN = Annals of the Russian academy of medical sciences. 2013;9:42–45.
- Kiktenko A.I., Zlobina G.P., Shchurin M.R., Kleshchinov V.N Byulleten' eksperimental'noi biologii i meditsiny = Bulletin of experimental biology and medicine. 1991;112(11):485–488.
- Zlobina G.P., Brusov O.S., Morozova M.A., Beniashvili A.G. Zhurnal nevrologii i psikhiatrii = Journal of neurology and psychiatry. 2009;109(10):47–50.
- Lambert M., Karow A., Leucht S., Schimmelmann B.G., Naber D. Dialogues Clin. Neurosci. 2010; 12 (3): 393–407.
- Helldin L., Kane J.M., Karilampi U., Norlander T., Archer T.
- J. Psychiatr. Res. 2006; 40 (8): 738–745.
- Wobrock T., Kohler J., Klein P., Falkai P. Acta Psychiatr. Scand. 2009; 120 (2): 120–128.
- Lehman A.F., Carpenter W.T., Goldman H.H., Stein-wachs D.M. Schizophr. Bull. 1995; 21: 669–675.
- Mosolov S.N.,Potapov A.V., Dedyurina Yu.M., Ushakov Yu.V., Tsukarzi E.E. Zhurnal nevrologii i psikhiatrii = Journal of neurology and psychiatry. 2010;110(5):71–75.
- Gorwood P., Peuskens J. Eur. Psychiatry. 2012; 27 (3): 170–1.
Supplementary files
